| Management target | Revenue 11.0% FY27 |
|---|
| Revenue growth | 6.4% YoY |
|---|---|
| Margins | EBITDA margin at 36.6% (up 650 bps YoY) |
| Demand visibility | Strong momentum across geographies in non-GPL portfolio |
| Management confidence | High; confident in momentum sustainability |
Growth
Revenue grew 6.4% YoY, while EBITDA and PAT grew 29.1% and 31.8% YoY respectively. Non-GPL business grew 26.5% YoY.
Outlook
Management guides 10-12% revenue growth for FY27 with 30-32% EBITDA margins. Significant 465 KL greenfield expansion underway at Solapur.
Risks
GPL business declined 52.6% YoY due to inventory rationalization; ongoing geopolitical uncertainties noted in regulated markets.
Last quarter's promises, checked
Delivered
- EBITDA Margin 30-32% → delivered 36.6% (= BEAT)
- Revenue Growth 5.7% CAGR (FY24-26) → delivered 6.4% YoY (= BEAT)
- Solapur Phase 1 operational Q2 FY27 → delivered on track (= BEAT)
Partly delivered
- CDMO 2 contracts in early H2 FY27 → delivered 3.8% growth (= PARTIAL)
Investor Presentation filed with NSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,380.00
- Market cap
- ₹16,942 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.1×Sector 47.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
- Value
- ₹9.12 Cr
Alivus Life Sciences Business Update
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Annual Report
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.